# How much is the pharmaceutical industry worth?

> Global medicine spending reached about 1.94 trillion US dollars in 2025. Compare how IQVIA, EFPIA and Evaluate measure the market, the largest drug companies by revenue, and what drives growth.

The pharmaceutical industry is worth about **USD 1.94 trillion a year** when measured by what the world spends on medicines. That is IQVIA's estimate for 2025, counted at the prices paid to manufacturers before confidential rebates, and IQVIA expects the total to pass USD 2.6 trillion by 2030. North America buys more than half of the world's prescription medicines by value.

Other serious estimates come out lower, between about USD 1.3 trillion and USD 1.7 trillion, because they count only audited prescription sales or forecast sales on a different basis. Among companies, Eli Lilly reported the highest medicine revenue in 2025, USD 65.2 billion, as GLP-1 drugs for diabetes and obesity became the industry's largest source of growth.

## How much is the pharmaceutical industry worth?

IQVIA estimates global medicine spending at USD 1,939 billion in 2025, up about 9% from USD 1,774 billion in 2024. Its forecast puts 2026 at USD 2,080 billion to USD 2,110 billion and 2030 at USD 2,630 billion to USD 2,660 billion, growth of 5% to 8% a year.

![Global medicine spending rising from 1.664 trillion US dollars in 2023 to a midpoint forecast of 2.645 trillion US dollars in 2030](/images/charts/global-pharmaceutical-market-2023-2030.webp '**Figure 1. Global medicine spending, 2023 to 2030.** Spending before off-invoice discounts and rebates, in US dollars. Values from 2026 onward are the midpoints of IQVIA forecast ranges. Sources: [IQVIA Institute (2026)](https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026), as reproduced by [Lupin (2026)](https://lupin.com/integrated-report-2026/business-review.html).')

IQVIA counts the amount spent buying medicines from manufacturers before off-invoice discounts and rebates. That is an invoice measure, closer to list price than to the revenue companies keep. The 2025 value also comes from IQVIA's September 2025 market forecast, so it is a late-year estimate rather than a final audited total.

The longer series shows how the market reached this size. Spending rose from USD 1,109 billion in 2016 to USD 1,316 billion in 2020, about 4% a year, then jumped to USD 1,570 billion in 2021 as COVID-19 vaccines and treatments were added. It has grown about 8% a year since.

## Why do estimates of the pharmaceutical market differ?

Published estimates for the same year differ by hundreds of billions of dollars because they measure different things: invoice spending or net revenue, all medicines or prescription medicines only, recorded sales or forecasts. Table 1 sets the main figures side by side.

  <caption><strong>Table 1. Recent estimates of the pharmaceutical market by source.</strong> Values in US dollars as published by each source. Sources: Lupin (2026), IQVIA Institute (2026), EFPIA (2026), Evaluate (2026), IQVIA Institute (2026), IQVIA Institute (2025).</caption>
  <thead>
    <tr>
      <th>Source</th>
      <th>Year</th>
      <th>Value</th>
      <th>What it measures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IQVIA Institute</td>
      <td>2025</td>
      <td>USD 1.94 trillion</td>
      <td>Spending on medicines bought from manufacturers, before off-invoice discounts and rebates</td>
    </tr>
    <tr>
      <td>IQVIA Institute</td>
      <td>2030 forecast</td>
      <td>USD 2.63 to 2.66 trillion</td>
      <td>Same measure, growing 5% to 8% a year</td>
    </tr>
    <tr>
      <td>EFPIA, from IQVIA MIDAS</td>
      <td>2025</td>
      <td>USD 1.67 trillion (EUR 1.48 trillion)</td>
      <td>Audited retail and hospital sales of prescription medicines at ex-manufacturer prices</td>
    </tr>
    <tr>
      <td>Evaluate World Preview</td>
      <td>2026 forecast</td>
      <td>About USD 1.3 trillion</td>
      <td>Worldwide prescription drug sales, forecast to exceed USD 2 trillion in 2032</td>
    </tr>
    <tr>
      <td>IQVIA Institute, United States</td>
      <td>2025</td>
      <td>USD 606 billion</td>
      <td>US spending at net prices, after rebates and discounts</td>
    </tr>
    <tr>
      <td>IQVIA Institute, oncology</td>
      <td>2024</td>
      <td>USD 252 billion</td>
      <td>Worldwide spending on cancer medicines at list prices</td>
    </tr>
  </tbody>

The largest gap is between invoice and net prices. In the United States, rebates, discounts and other concessions now offset about 46% of invoice value, which is why IQVIA puts US spending at net prices at USD 606 billion for 2025. Companies report revenue after these deductions, so totals built from company sales sit well below IQVIA's headline figure.

The second gap is scope. EFPIA's figure, taken from IQVIA's audited MIDAS sales data, covers only prescription medicines sold through retail pharmacies and hospitals and comes to USD 1,668 billion for 2025. Evaluate's forecast of prescription drug sales, about USD 1.3 trillion in 2026, is lower again. The sources agree on direction, though: each expects growth of roughly 5% to 8% a year into the early 2030s.

## Where is the money spent?

North America, meaning the United States and Canada, accounted for 54.7% of world prescription medicine sales in 2025. Europe accounted for 23.7%, China for 6.5% and Japan for 3.5%. The imbalance is larger for new medicines: 74.1% of sales of medicines launched from 2020 through 2024 came from the US market, against 15.6% from the five largest European markets.

US spending at net prices grew 10.6% in 2025, from USD 548 billion to USD 606 billion. GLP-1 and GIP medicines for diabetes and obesity added USD 14 billion of that growth, and patients paid a record USD 110 billion out of pocket. Part of the US premium comes from specialty medicines with very high prices, including the [most expensive drugs](/guides/most-expensive-drugs) in the world, one-time gene therapies with multimillion-dollar list prices.

## Which pharmaceutical companies make the most money?

Eli Lilly reported the highest medicine revenue of any company in 2025: USD 65.2 billion, up 45% in a year. Merck followed at USD 65.0 billion, a total that includes USD 6.4 billion from animal health. Nine other large drugmakers each reported between about USD 47 billion and USD 63 billion from medicines.

  <caption><strong>Table 2. Largest pharmaceutical companies by 2025 revenue.</strong> Full-year results for calendar 2025. For Johnson & Johnson and Roche, only the pharmaceutical segment is shown. Change is in each company's reporting currency. We converted CHF, EUR and DKK to US dollars at Federal Reserve 2025 average exchange rates. Sources: Eli Lilly, Merck, Pfizer, AbbVie, Johnson & Johnson, AstraZeneca, Roche, Novartis, Sanofi, Bristol Myers Squibb and Novo Nordisk (2026); Federal Reserve (2026).</caption>
  <thead>
    <tr>
      <th>Company</th>
      <th>2025 revenue as reported</th>
      <th>USD billions</th>
      <th>Change from 2024</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Eli Lilly</td>
      <td>USD 65,179 million</td>
      <td>65.2</td>
      <td>+45%</td>
    </tr>
    <tr>
      <td>Merck & Co.</td>
      <td>USD 65,011 million</td>
      <td>65.0</td>
      <td>+1%</td>
    </tr>
    <tr>
      <td>Pfizer</td>
      <td>USD 62,579 million</td>
      <td>62.6</td>
      <td>-2%</td>
    </tr>
    <tr>
      <td>AbbVie</td>
      <td>USD 61,160 million</td>
      <td>61.2</td>
      <td>+9%</td>
    </tr>
    <tr>
      <td>Johnson & Johnson, Innovative Medicine</td>
      <td>USD 60,401 million</td>
      <td>60.4</td>
      <td>+6%</td>
    </tr>
    <tr>
      <td>AstraZeneca</td>
      <td>USD 58,739 million</td>
      <td>58.7</td>
      <td>+9%</td>
    </tr>
    <tr>
      <td>Roche, Pharmaceuticals Division</td>
      <td>CHF 47,669 million</td>
      <td>57.4</td>
      <td>+3%</td>
    </tr>
    <tr>
      <td>Novartis</td>
      <td>USD 54,532 million</td>
      <td>54.5</td>
      <td>+8%</td>
    </tr>
    <tr>
      <td>Sanofi</td>
      <td>EUR 43,626 million</td>
      <td>49.3</td>
      <td>+6%</td>
    </tr>
    <tr>
      <td>Bristol Myers Squibb</td>
      <td>USD 48,194 million</td>
      <td>48.2</td>
      <td>0%</td>
    </tr>
    <tr>
      <td>Novo Nordisk</td>
      <td>DKK 309,064 million</td>
      <td>46.7</td>
      <td>+6%</td>
    </tr>
  </tbody>

Whole companies can be larger than their medicine business. Johnson & Johnson's total sales were USD 94.2 billion including medical devices, and Roche's group sales of CHF 61.5 billion include diagnostics. Growth also diverged sharply. Almost all of Lilly's USD 20 billion increase came from tirzepatide, while Pfizer's revenue fell as COVID-19 product sales declined; without Comirnaty and Paxlovid, Pfizer grew 6%.

Stock-market value is a separate measure that changes every trading day and leaves out private companies. On November 21, 2025, Eli Lilly briefly became the first drugmaker valued at USD 1 trillion, more than twice the value of Johnson & Johnson, its closest pharmaceutical rival.

## What is driving pharmaceutical market growth?

GLP-1 medicines for diabetes and obesity are the largest single source of growth. Lilly's [tirzepatide](/guides/semaglutide-vs-tirzepatide) brands, Mounjaro and Zepbound, sold USD 36.5 billion in 2025. Novo Nordisk's semaglutide brands, [Ozempic](/guides/ozempic-statistics), Wegovy and Rybelsus, sold DKK 228.3 billion, about USD 34.5 billion. Each molecule outsold Merck's cancer immunotherapy Keytruda, at USD 31.7 billion.

Cancer medicines are the other main driver. IQVIA put worldwide oncology spending at list prices at USD 252 billion in 2024 and expects USD 441 billion by 2029. It names oncology and immunology as the main sources of growth through 2030, with both expected to slow later in the decade.

[Patent expiries](/guides/how-long-does-a-drug-patent-last) pull the other way. Evaluate estimates that more than USD 500 billion of sales is at risk from generic competition between 2026 and 2032, and that revenue has to be replaced by new launches. IQVIA counted [79 new active substances](/guides/drug-discovery-trends) launched worldwide in 2025, 53 of them in the United States.

## How much does the pharmaceutical industry spend on advertising and marketing?

US prescription-drug advertising totaled about USD 10.1 billion in 2024 across television, digital, paid social, print, radio, and outdoor media. Television accounted for roughly half of the total.

IQVIA's narrower measure puts direct-to-consumer television advertising above USD 6 billion in 2024. It counted 75 drug brands that each spent at least USD 10 million on television.

Advertising is only one part of marketing. The most complete peer-reviewed US estimate found USD 26.9 billion in prescription-drug and disease-awareness marketing in 2016, measured in 2016 dollars. USD 20.3 billion went to health professionals, while USD 6 billion went to consumer prescription-drug advertising.

![US pharmaceutical promotion spending in 2016, led by free samples, consumer drug advertising, and prescriber detailing](/images/charts/us-pharmaceutical-marketing-components-2016.webp '**Figure 2. US pharmaceutical promotion spending by component, 2016.** Annual spending in 2016 US dollars. Source: [Schwartz and Woloshin (2019)](https://jamanetwork.com/journals/jama/fullarticle/2720029).')

The professional total included USD 13.5 billion in free samples, USD 5.6 billion in prescriber detailing, and USD 979 million in direct physician payments tied to specific drugs. Disease-awareness campaigns added USD 430 million.

These figures should not be combined across years. The 2024 figure tracks paid prescription-drug media, while the 2016 study also counted samples, sales visits, physician payments, and unbranded disease promotion.

## How much profit does the pharmaceutical industry make?

There is no audited global profit total for every pharmaceutical company. One documented benchmark is more than USD 112 billion in combined 2022 profit across ten large drug companies.

Profit margin is easier to compare across companies than a cash total. A JAMA study of 35 large pharmaceutical companies from 2000 through 2018 found a median annual net income margin of 13.8%, compared with 7.7% for 357 other large public companies. The pharmaceutical group reported USD 1.9 trillion in cumulative net income on USD 11.5 trillion in revenue over the 19-year period.

The same study found a 76.5% median gross margin and a 29.4% median margin for earnings before interest, taxes, depreciation, and amortization. Gross, operating, and net margins measure different stages of the income statement. The authors also cautioned that the gap narrowed after controlling for company size, R&D spending, and time trends.

Profit studies of public companies leave failed startups and private firms outside the sample. Results also move sharply when patents expire, acquisitions close, or a major product launches. A long-run margin and a defined company sample are more informative than an unsourced claim about total “Big Pharma profit.”

## How much does the pharmaceutical industry spend on lobbying?

The US pharmaceutical and health products industry spent a record USD 457.3 million on federal lobbying in 2025. It spent another USD 131 million in the first quarter of 2026.

This category is broader than prescription-drug manufacturers. It includes pharmaceutical and biological products, diagnostics, medical devices, nutritional products, and other health-product organizations.

The longer record shows how exceptional recent spending is. From 1999 through 2018, the industry spent USD 4.7 billion on federal lobbying, an inflation-adjusted average of USD 233 million a year. It also contributed USD 414 million to federal candidates and political groups and USD 877 million to state candidates and committees over that period.

Lobbying is separate from campaign contributions and advertising. Adding the three together would mix spending governed by different laws and recorded in different databases.

## How many pharmaceutical and biotechnology companies are there?

There is no official worldwide company census. Biotechgate lists 23,710 biotechnology companies in its database, while Citeline counted 7,057 companies with active pharmaceutical R&D pipelines at the start of 2026.

The two figures cover different groups. Biotechgate includes therapeutic and diagnostic developers, R&D services, contract manufacturers, genomics, agricultural biotech, food, industrial biotech, and other biological businesses. Citeline's narrower count covers companies developing drugs.

Those pharmaceutical R&D companies had 22,940 active candidates at the start of 2026. They move through a pipeline that can include laboratory screening, [molecular docking](/app/autodock-vina), preclinical work, and clinical trials. The [medicine count](/guides/how-many-medicines-are-there-in-the-world) is much smaller because about [nine in ten](/guides/clinical-trial-failure-rate) clinical candidates fail, and the programs that succeed carry the [cost of failed research](/guides/drug-development-cost).

The best available global employment estimate puts direct pharmaceutical employment at 7.8 million people in 2022. An industry-commissioned economic model estimated another 44.7 million jobs in supplier industries and 22.4 million jobs supported by worker spending, for 74.9 million direct, indirect, and induced jobs combined.

Direct employment is the cleaner workforce figure. The 74.9 million total comes from an economic-impact model rather than company payrolls.

ProteinIQ. "How much is the pharmaceutical industry worth?" Published July 30, 2026. Accessed [your access date]. https://proteiniq.io/guides/how-much-is-the-pharmaceutical-industry-worth